AstraZeneca Archives - Pharmaphorum

Cost of AZ’s new Cambridge HQ ‘has more than doubled’

The cost of AstraZeneca’s new R&D hub and corporate headquarters in Cambridge has swelled to £750 million, more

Cost of AZ’s new Cambridge HQ ‘has more than doubled’

https://pharmaphorum.com/news/cost-of-azs-new-cambridge-hq-has-more-than-doubled/

AstraZeneca ends another Calquence trial early

For the second time in the space of a month AstraZeneca has stopped a trial of its chronic

AstraZeneca ends another Calquence trial early

https://pharmaphorum.com/news/astrazeneca-ends-another-calquence-trial-early/

AZ/Merck & Co wow ASCO with pancreatic cancer data

Finding targeted therapies for pancreatic cancer has long been an issue for pharma, meaning that for decades the

AZ/Merck & Co wow ASCO with pancreatic cancer data

https://pharmaphorum.com/news/az-merck-co-wow-asco-with-pancreatic-cancer-data/

AZ/Merck & Co reveal data supporting PARP drug in prostate cancer

PARP, or poly (ADP-ribose) polymerase, inhibitors may have an amusing-sounding name but an increasing body of evidence suggest

AZ/Merck & Co reveal data supporting PARP drug in prostate cancer

https://pharmaphorum.com/news/az-merck-co-reveal-data-supporting-parp-drug-in-prostate-cancer/

AZ pulls back on Inovio immuno-oncology pact

AstraZeneca has decided to trim back its 2015 alliance with Inovio Pharmaceuticals, which focused on combining the biotech’s

AZ pulls back on Inovio immuno-oncology pact

https://pharmaphorum.com/news/az-pulls-back-on-inovio-immuno-oncology-pact/

Oncology round-up: AZ and Daiichi score key trial win with breast cancer antibody and more

AZ and Daiichi Sankyo announced positive top-line results from the pivotal phase 2 DESTINY-Breast01 trial of trastuzumab deruxtecan,

Oncology round-up: AZ and Daiichi score key trial win with breast cancer antibody and more

https://pharmaphorum.com/views-and-analysis/oncology-round-up-az-and-daiichi-score-key-trial-win-with-breast-cancer-antibody-and-more/

The Pharma Social Media Conference

Pharma Social Media

The Pharma Social Media Conference

https://pharmaphorum.com/events/the-pharma-social-media-conference/

AstraZeneca shows cardiovascular safety for roxadustat

AstraZeneca has announced that pooled analyses of the phase III trials for its kidney disease drug roxadustat confirm

AstraZeneca shows cardiovascular safety for roxadustat

https://pharmaphorum.com/news/astrazeneca-shows-cardiovascular-safety-for-roxadustat/

AZ and Daiichi to file new breast cancer drug after trial success

In March AstraZeneca asked investors for $3.5 billion to fund a collaboration with Daiichi Sankyo over a new

AZ and Daiichi to file new breast cancer drug after trial success

https://pharmaphorum.com/news/az-and-daiichi-to-file-trastuzumab-deruxtecan/

Trending

AstraZeneca

Hello World

Cost of AZ’s new Cambridge HQ ‘has more than doubled’

AstraZeneca ends another Calquence trial early

AZ/Merck & Co wow ASCO with pancreatic cancer data

AZ/Merck & Co reveal data supporting PARP drug in prostate cancer

AZ pulls back on Inovio immuno-oncology pact

Oncology round-up: AZ and Daiichi score key trial win with breast cancer antibody and more

The Pharma Social Media Conference

AstraZeneca shows cardiovascular safety for roxadustat

AZ and Daiichi to file new breast cancer drug after trial success

Search

Advanced Search

Trending

AstraZeneca

Hello World